Dendritic cell and melanoma: Dendritic cell therapy combined with hyperthermia doubles survival (from 6 to 13 months) for patients with advanced melanoma. Article posted October 2007
June 22, 2011: Please read the recently added information about Dr. Robert Gorter and Medical Center in Cologne this information: My experience with dr.Robert Gorter and the Medical Center Cologne. A warning
And click here for addresses of clinics in Germany, where dendritic cell therapy is given .
October 25, 2007. Source: 1: Int J Cancer. 2007 June 1, 120 (11) :2418-25.
Dendritic cell therapy combined with hyperthermia indicates systemic anti-tumor effects in advanced melanoma . The group that received hyperthermia had a lot more extra benefit from the dendritic cell therapy than the group without hyperthermia. The overall survival was from six months to 13 months. Remember that all patients were basically incurable and almost everything had been tried. A doubling of overall survival is an excellent result.
Intratumoral injection of dendritic cells in combination with local hyperthermia induces systemic antitumor effect in patients with advanced melanoma. Guo Y, Zhu J, Sheng X, Wang X, Qu L, Han Y, Liu Y, Zhang H, Huo L, Zhang S, Lin B, Yang Z. Department of Renal Cancer and Melanoma, Peking University School of Oncology, Beijing Cancer Hospital, Beijing, PR China. guoj307@126.com Dendritic cells (DC) are potent antigen-presenting cells can present tumor antigens That chaperoned by heat shock proteins (HSPs), while local hyperthermia (LHT) can Increase the expression of HSPs. In this study, we are determining if intratumoral injection of immature DC after LHT (LHT + IT-DC) induces systemic antitumor immunity in patients with advanced melanoma, and Investigate the potential Immunological Mechanisms Involved in the treatments. Patients were randomly Assigned to intratumoral administration of autologous immature DC triweekly, with (LHT + IT-DC, arm A, n = 9) or without (IT-DC, arm B, n = 9) LHT.
Our results showed there were no That grade 3 / 4 toxicities. The time to progress (TTP) of arm A was 5 months, significantly longer than in arm B That (2 months, p <0.05). However, the overall survival time was no statistical difference (13 months vs. 6. Months, p> 0.05) Between the two groups. Our ELISPOT assay showed a significantly Increased melanoma-specific IFN-gamma production in arm A That suggests LHT + IT-DC was more effective in the induction of cytotoxic T lymphocytes (CTL) than IT-DC alone. More Further, we detected an Increased expression 4 hr after the HSPs first LHT, an enhanced Th1/Th2 chemokine production 24 hr after the first LHT + IT-DC treatment, a promoted migration to afferent lymph nodes or DC, and a Decreased infiltration or regulatory T cells (CD4 (+) CD25 (+)) and an Increased infiltration of active CTL (CD8 (+) CD28 (+)) 48 hr after the third DC injection in arm A patient. Therefore, LHT + IT-DC can induce effective specific antitumor immunity and a Th1-polarized immune Facilitate response in patients with advanced melanoma. PMID: 17294445 [PubMed - indexed for MEDLINE]
